Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Bone and Cartilage Regenerative Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
J Tissue Eng Regen Med. 2021 Feb;15(2):103-115. doi: 10.1002/term.3149. Epub 2020 Nov 18.
Human synovium-derived stem cells (hSSCs) are an attractive source of cells for cartilage repair. At present, the quality of tissue and techniques used for cartilage regeneration have scope for improvement. A small compound, TD-198946, was reported to enhance chondrogenic induction from hSSCs; however, other applications of TD-198946, such as priming the cell potential of hSSCs, remain unknown. Our study aimed to examine the effect of TD-198946 pretreatment on hSSCs. HSSCs were cultured with or without TD-198946 for 7 days during expansion culture and then converted into a three-dimensional pellet culture supplemented with bone morphogenetic protein-2 (BMP2) and/or transforming growth factor beta-3 (TGFβ3). Chondrogenesis in cultures was assessed based on the GAG content, histology, and expression levels of chondrogenic marker genes. Cell pellets derived from TD-198946-pretreated hSSCs showed enhanced chondrogenic potential when chondrogenesis was induced by both BMP2 and TGFβ3. Moreover, cartilaginous tissue was efficiently generated from TD-198946-pretreated hSSCs using a combination of BMP2 and TGFβ3. Microarray analysis revealed that NOTCH pathway-related genes and their target genes were significantly upregulated in TD-198946-treated hSSCs, although TD-198946 alone did not upregulate chondrogenesis related markers. The administration of the NOTCH signal inhibitor diminished the effect of TD-198946. Thus, TD-198946 enhances the chondrogenic potential of hSSCs via the NOTCH3 signaling pathway. This study is the first to demonstrate the gradual activation of NOTCH3 signaling during chondrogenesis in hSSCs. The priming of NOTCH3 using TD-198946 provides a novel insight regarding the regulation of the differentiation of hSSCs into chondrocytes.
人滑膜干细胞(hSSCs)是软骨修复的有吸引力的细胞来源。目前,用于软骨再生的组织和技术的质量还有改进的空间。一种小分子化合物 TD-198946 被报道可增强 hSSCs 的软骨诱导;然而,TD-198946 的其他应用,如启动 hSSCs 的细胞潜能,仍不清楚。我们的研究旨在研究 TD-198946 预处理对 hSSCs 的影响。在扩展培养期间,将 hSSCs 与或不与 TD-198946 一起培养 7 天,然后转化为补充有骨形态发生蛋白 2(BMP2)和/或转化生长因子β3(TGFβ3)的三维球体培养物。根据 GAG 含量、组织学和软骨形成标志物基因的表达水平评估培养物中的软骨形成。来自 TD-198946 预处理的 hSSCs 的细胞球在同时诱导 BMP2 和 TGFβ3 时显示出增强的软骨形成潜力。此外,使用 BMP2 和 TGFβ3 的组合可从 TD-198946 预处理的 hSSCs 中有效生成软骨组织。微阵列分析显示,尽管 TD-198946 本身不能上调软骨形成相关标志物,但 NOTCH 通路相关基因及其靶基因在 TD-198946 处理的 hSSCs 中显著上调。NOTCH 信号抑制剂的给药减弱了 TD-198946 的作用。因此,TD-198946 通过 NOTCH3 信号通路增强 hSSCs 的软骨形成潜力。这项研究首次证明了 NOTCH3 信号在 hSSCs 软骨形成过程中的逐渐激活。使用 TD-198946 启动 NOTCH3 为 hSSCs 向软骨细胞分化的调控提供了新的见解。